Skip to content
Storytelling Co – Lifestyle
Author:
Alector, Inc.
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
October 7, 2026
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
October 5, 2026
Alector to Participate in Upcoming Healthcare Conferences
September 3, 2026
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
April 29, 2026